PDC-E3BP is not a dominant T-cell autoantigen in primary biliary cirrhosis


Prof. David E.J. Jones, Liver Research Group, School of Clinical Medical Sciences, 4th Floor, William Leech Building, The Medical School, Framlington Place, Newcastle-upon-Tyne NE2 4HH, UK.
Tel: +44 191 222 5784
Fax: +44 191 222 0723
e-mail: D.E.J.Jones@ncl.ac.uk


Abstract: Background: Autoantibody responses reactive with the E2 and E3BP components of pyruvate dehydrogenase complex (PDC), which characterise primary biliary cirrhosis (PBC) crossreact, precluding the identification, from serological studies, of the antigen to which the principal breakdown of tolerance occurs. Although autoreactive T-cell responses to PDC-E2 have been well characterised it is, at present, unclear whether T-cell tolerance breakdown also occurs to PDC-E3BP. The aims of this study were to characterise autoreactive T-cell responses to PDC-E3BP in PBC and potential factors regulating their expression.

Methods: Peripheral blood T-cell proliferative responses to purified recombinant human PDC-E2 and PDC-E3BP at a range of concentrations were characterised in PBC patients and control subjects.

Results: T-cell proliferative responses to both E2 and E3BP were absent from control subjects (median peak stimulation index (SI) to PDC-E2 1.2 [range 0.3–1.9], 0/10 positive (SI>2.32), median peak SI to PDC-E3BP 1.1 [0.7–2.1]], 0/10 positive). Significant responses to PDC-E2 were seen in the majority of patients (median peak SI 11.4 [0.4–24.4], 17/20 (85%) positive) but to PDC-E3BP in only a minority (median peak SI 1–9 [0.6–9.95], 8/20 (40%) positive). Where responses to PDC-E3BP were seen they were universally secondary to responses to PDC-E2.

Conclusions: Despite the presence of antibodies reactive with PDC-E3BP in the majority of PBC patients this self-protein is not a dominant T-cell autoantigen in PBC.